Bevacizumab in combination with oxaliplatin and either 5-fluorouracil or capecitabine for the treatment of metastatic colorectal cancer

ERG additional analyses relating to the cost of Oxaliplatin as requested by NICE/Appraisal Committee at Appraisal Committee meeting 27 October 2010

With APAS analysis:

Changes were applied to model version 22nd March 2010 named: AVASTIN MCRC_NICE_2by2 ERG changes excl Adjuvant with ACD

			ICERs	
Cost of oxaliplatin	Cost per 100mg		B-XELOX vs. XELOX	B-FOLFOX vs. FOLFOX
BNF57 cost	£	313.50	£29,975	£24,604
90% discount on BNF57 cost	£	31.35	£68,140	£70,470
95% discount on BNF57 cost	£	15.68	£70,260	£73,018

Without APAS analysis:

Changes applied to model version October 2009 named: AVASTIN MCRC_NICE_2by2 ERG changes excl Adjuvant no APAS.xls

The model assumes that duration in treatment with oxaliplatin is slightly longer with the addition of bevacizumab hence reducing the cost of oxaliplatin slightly reduces the incremental costs.

			ICERs	
Cost of oxaliplatin	Cost per 100mg		B-XELOX vs. XELOX	B-FOLFOX vs. FOLFOX
BNF57 cost	£	313.50	£92,702	£96,691
90% discount on BNF57 cost	£	31.35	£88,619	£91,934
95% discount on BNF57 cost	£	15.68	£88,392	£91,670